Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 3:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo for Amlodipine Clear all
Active, not recruiting Phase 4 Interventional

The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans

NCT03938389
View directory record Official record
Conditions
PreDiabetes, Impaired Glucose Tolerance, Obesity, Blood Pressure
Interventions
Sacubitril-Valsartan Tab 97-103 MG, Valsartan 160mg, Placebo Oral Tablet
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

NCT00417170
View directory record Official record
Conditions
High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
Interventions
Aliskiren, Amlodipine, Placebo Aliskiren, Placebo Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Sep 24, 2026, 3:53 AM EDT
Terminated Phase 3 Interventional Results available

Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes

NCT02850081
View directory record Official record
Conditions
Carotid Artery Stenosis, Strokes
Interventions
Statin, Atorvastatin, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Ridgewood, New Jersey • Albany, New York • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 24, 2026, 3:53 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

NCT02232880
View directory record Official record
Conditions
Hypertension
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Results available

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

NCT05103332
View directory record Official record
Conditions
Hypertension
Interventions
Indapamide, Amlodipine, Olmesartan, Placebo, Zilebesiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
74
States / cities
Mesa, Arizona • Tempe, Arizona • Bell Gardens, California + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Not applicable Interventional

Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)

NCT01354613
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension
Interventions
Dobutamine, Amlodipine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Sep 24, 2026, 3:53 AM EDT
Recruiting Phase 2Phase 3 Interventional

Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries

NCT06424834
View directory record Official record
Conditions
Angina Pectoris, Microvascular Angina, Vasospastic Angina, Myocardial Bridge of Coronary Artery
Interventions
Amlodipine, Nebivolol, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

NCT00739973
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, Aliskiren 150 mg tablet, Aliskiren 300 mg tablet, Amlodipine 5 mg capsule, Amlodipine 10 mg capsule, Aliskiren/amlodipine 150/5 mg tablet, Aliskiren/amlodipine 150/10 mg tablet, Aliskiren/amlodipine 300/5 mg tablet, Aliskiren/amlodipine 300/10 mg tablet
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 5, 2011 · Synced Sep 24, 2026, 3:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

Sympathetic Mechanisms in Obesity-Crossover Design

NCT05312892
View directory record Official record
Conditions
Obesity, Hypertension
Interventions
Amlodipine, Moxonidine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Not applicable Interventional Results available

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

NCT02130687
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypertension
Interventions
Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT)
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

NCT00765674
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 8, 2011 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 4 Interventional Results available

A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk

NCT00412113
View directory record Official record
Conditions
Dyslipidemia, Hypertension
Interventions
Amlodipine besylate, Amlodipine besylate/atorvastatin calcium single pill combination
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
51
States / cities
Birmingham, Alabama • Mesa, Arizona • Garden Grove, California + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 24, 2026, 3:53 AM EDT
Recruiting Phase 3 Interventional

A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)

NCT06150560
View directory record Official record
Conditions
Coarctation of Aorta, High Blood Pressure
Interventions
Losartan, Amlodipine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 24, 2026, 3:53 AM EDT
Terminated Not applicable Interventional Results available

Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance

NCT01252238
View directory record Official record
Conditions
Insulin Sensitivity, Aortic Compliance, Diastolic Function
Interventions
Aliskiren, Valsartan and Aliskiren, Amlodipine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Results available

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension

NCT00281580
View directory record Official record
Conditions
Hypertension
Interventions
Amlodipine 5 mg, Placebo, Telmisartan 20 mg, Telmisartan 40 mg, Amlodipine 10 mg, Telmisartan 80 mg, Amlodipine 2.5 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
101
States / cities
Fairhope, Alabama • Huntsville, Alabama • Chandler, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

NCT00591266
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan Medoxomil and amlodipine, Amlodipine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Sep 24, 2026, 3:53 AM EDT
Terminated Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

NCT01368536
View directory record Official record
Conditions
Hypertension, Stage 2 Hypertension, Diabetes
Interventions
Valturna, Amlodipine, Chlorthalidone, Placebo of Valturna Tablet, Placebo Capsule
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
95
States / cities
Athens, Alabama • Florence, Alabama • Huntsville, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 4 Interventional Results available

Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism

NCT02034435
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Low Salt diet plus Placebo tablet, Low Sodium diet plus Salt tablet, Epleronone, Amlodipine
Other · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

NCT01692301
View directory record Official record
Conditions
Hypertension
Interventions
LCZ696, Olmesartan, LCZ696 matching placebo, Olmesartan matching placebo, amlodipine, hydrochlorothiazide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
11
States / cities
Clearwater, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 24, 2026, 3:53 AM EDT
Terminated Phase 3 Interventional Results available

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People

NCT01259297
View directory record Official record
Conditions
Cardiovascular Events
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo for Aliskiren, Placebo for Amlodipine, Placebo for Hydrochlorothiazide (HCTZ)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older
Enrollment
2,336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Northridge, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Avanafil and Enalapril or Amlodipine

NCT01117038
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
avanafil and enalapril, avanafil and amlodipine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
40 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 9, 2011 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension

NCT04518306
View directory record Official record
Conditions
Hypertension
Interventions
Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo
Drug
Lead sponsor
George Medicines PTY Limited
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 24, 2026, 3:53 AM EDT